Glaukos' Q4 preliminary sales rise 36%, beat estimates

Reuters01-14

Glaukos' Q4 preliminary sales rise 36%, beat estimates

Overview

Ophthalmic pharma firm's preliminary Q4 net sales rose 36%, beating analyst expectations
Company ended Q4 with $283 mln in cash and no debt

Outlook

Glaukos reaffirms 2026 revenue guidance of $600 mln to $620 mln
Company expects sustained growth momentum due to novel technology pipeline

Result Drivers

IDOSE TR SALES - iDose TR contributed $45 mln to U.S. Glaucoma net sales in Q4, highlighting its strong market performance
CORNEAL HEALTH SALES - Corneal Health net sales reached $24 mln in Q4, contributing to overall sales growth
INTERNATIONAL GROWTH - International Glaucoma net sales were $33 mln in Q4, supporting global sales increase

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Sales	Beat	$143 mln	$131.20 mln (14 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Glaukos Corp is $127.50, about 15% above its January 12 closing price of $110.91

Press Release: ID:nBwb0Y99a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603658325?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 05:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603658325","market":"fut","top_or_hot":-1,"title":"Glaukos' Q4 preliminary sales rise 36%, beat estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Glaukos' Q4 preliminary sales rise 36%, beat estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Ophthalmic pharma firm's preliminary Q4 net sales rose 36%, beating analyst expectations</p></li><li><p>Company ended Q4 with $283 mln in cash and no debt</p></li></ul><p><span>Outlook</span></p><ul><li><p>Glaukos reaffirms 2026 revenue guidance of $600 mln to $620 mln</p></li><li><p>Company expects sustained growth momentum due to novel technology pipeline</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>IDOSE TR SALES - iDose TR contributed $45 mln to U.S. Glaucoma net sales in Q4, highlighting its strong market performance</p></li><li><p>CORNEAL HEALTH SALES - Corneal Health net sales reached $24 mln in Q4, contributing to overall sales growth</p></li><li><p>INTERNATIONAL GROWTH - International Glaucoma net sales were $33 mln in Q4, supporting global sales increase</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Sales</p></td><td><p>Beat</p></td><td><p>$143 mln</p></td><td><p>$131.20 mln (14 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 1 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/GKOS\">Glaukos Corp</a> is $127.50, about 15% above its January 12 closing price of $110.91</p></li></ul><p>Press Release: <span>ID:nBwb0Y99a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaukos' Q4 preliminary sales rise 36%, beat estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaukos' Q4 preliminary sales rise 36%, beat estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-14 05:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Glaukos' Q4 preliminary sales rise 36%, beat estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Ophthalmic pharma firm's preliminary Q4 net sales rose 36%, beating analyst expectations</p></li><li><p>Company ended Q4 with $283 mln in cash and no debt</p></li></ul><p><span>Outlook</span></p><ul><li><p>Glaukos reaffirms 2026 revenue guidance of $600 mln to $620 mln</p></li><li><p>Company expects sustained growth momentum due to novel technology pipeline</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>IDOSE TR SALES - iDose TR contributed $45 mln to U.S. Glaucoma net sales in Q4, highlighting its strong market performance</p></li><li><p>CORNEAL HEALTH SALES - Corneal Health net sales reached $24 mln in Q4, contributing to overall sales growth</p></li><li><p>INTERNATIONAL GROWTH - International Glaucoma net sales were $33 mln in Q4, supporting global sales increase</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Sales</p></td><td><p>Beat</p></td><td><p>$143 mln</p></td><td><p>$131.20 mln (14 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 1 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/GKOS\">Glaukos Corp</a> is $127.50, about 15% above its January 12 closing price of $110.91</p></li></ul><p>Press Release: <span>ID:nBwb0Y99a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nL1N3YE13R:1","article_id":"2603658325","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603658325","pubTimestamp":1768338942,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Glaukos' Q4 preliminary sales rise 36%, beat estimatesOverviewOphthalmic pharma firm's preliminary Q4 net sales rose 36%, beating analyst expectationsCompany ended Q4 with $283 mln in cash and no debt","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","CMI":"康明斯","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","GKOS":"Glaukos Corp","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","BK4149":"建筑机械与重型卡车","BK4588":"碎股","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓"},"translate_title":"Glaukos第四季度初步销售额增长36%，超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":0.9,"CMI":0.9},"content_text":"Glaukos' Q4 preliminary sales rise 36%, beat estimatesOverviewOphthalmic pharma firm's preliminary Q4 net sales rose 36%, beating analyst expectationsCompany ended Q4 with $283 mln in cash and no debtOutlookGlaukos reaffirms 2026 revenue guidance of $600 mln to $620 mlnCompany expects sustained growth momentum due to novel technology pipelineResult DriversIDOSE TR SALES - iDose TR contributed $45 mln to U.S. Glaucoma net sales in Q4, highlighting its strong market performanceCORNEAL HEALTH SALES - Corneal Health net sales reached $24 mln in Q4, contributing to overall sales growthINTERNATIONAL GROWTH - International Glaucoma net sales were $33 mln in Q4, supporting global sales increaseKey DetailsMetricBeat/MissActualConsensus EstimateQ4 SalesBeat$143 mln$131.20 mln (14 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 1 \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy\"Wall Street's median 12-month price target for Glaukos Corp is $127.50, about 15% above its January 12 closing price of $110.91Press Release: ID:nBwb0Y99aFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603658325","isCrawlerRequest":true}